blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1756104

EP1756104 - TETRAHYDRONAPHTHYRIDINE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  21.10.2011
Database last updated on 28.09.2024
Most recent event   Tooltip04.10.2013Lapse of the patent in a contracting state
New state(s): HU		published on 06.11.2013  [2013/45]
Applicant(s)For:GB 
Pfizer Limited
Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
For:AT  BE  BG  CH  CY  CZ  DE  DK  EE  ES  FI  FR  GR  HU  IE  IS  IT  LI  LT  LU  MC  NL  PL  PT  RO  SE  SI  SK  TR 
Pfizer Inc.
235 East 42nd Street
New York, NY 10017 / US
[2010/50]
Former [2007/40]For:GB 
Pfizer Limited
Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
For:AT  BE  BG  CH  CY  CZ  DE  DK  EE  ES  FI  FR  GR  HU  IE  IS  IT  LI  LT  LU  MC  NL  PL  PT  RO  SE  SI  SK  TR 
PFIZER INC.
235 East 42nd Street
New York, N.Y. 10017 / US
Former [2007/09]For:GB 
Pfizer Limited
Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
For:AT  BE  BG  CH  CY  CZ  DE  DK  EE  ES  FI  FR  GR  HU  IE  IS  IT  LI  LT  LU  MC  NL  PL  PT  RO  SE  SI  SK  TR 
Lunn, Graham
Pfizer Global Research & Development Ramsgate Road Sandwhich
Kent CT13 9NJ / GB
Inventor(s)01 / LUNN, Graham, Pfizer Global R & D
Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
02 / MATHIAS, John Paul, Pfizer Global R & D
Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
03 / STRANG, Ross Sinclair, Pfizer Global R & D
Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
 [2007/09]
Representative(s)Laurent, Claire, et al
Pfizer
ATTENTION: ADDRESS INACTIVE - USE ASS-NR - CDR / FR
[N/P]
Former [2009/21]Laurent, Claire, et al
Pfizer Limited European Patent Department Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
Former [2009/20]Laurent, Claire, et al
Pfizer Limited European Patent Department Ramsgate Road
Sandwich, Kent CT13 9NJ / FR
Former [2008/44]Laurent, Claire, et al
Pfizer European Pharma Patent Department 23-25, avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
Former [2007/09]Laurent, Claire, et al
Pfizer European Pharma Patent Department 23-25, avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
Application number, filing date05736116.406.05.2005
[2007/09]
WO2005IB01267
Priority number, dateEP2004029122212.05.2004         Original published format: EP 04291222
[2007/09]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2005111036
Date:24.11.2005
Language:EN
[2005/47]
Type: A1 Application with search report 
No.:EP1756104
Date:28.02.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 24.11.2005 takes the place of the publication of the European patent application.
[2007/09]
Type: B1 Patent specification 
No.:EP1756104
Date:15.12.2010
Language:EN
[2010/50]
Search report(s)International search report - published on:EP24.11.2005
ClassificationIPC:C07D471/04, C07D519/00, A61K31/4745, A61K31/4985, A61K31/52, A61P25/00
[2007/09]
CPC:
C07D471/04 (EP,KR,US); A61K31/497 (KR); A61P1/08 (EP);
A61P11/00 (EP); A61P11/06 (EP); A61P15/00 (EP);
A61P25/00 (EP); A61P25/06 (EP); A61P25/08 (EP);
A61P25/18 (EP); A61P25/20 (EP); A61P25/22 (EP);
A61P25/24 (EP); A61P25/28 (EP); A61P27/16 (EP);
A61P29/00 (EP); A61P3/04 (EP); A61P35/00 (EP);
A61P37/08 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/09]
Extension statesAL12.12.2006
BA12.12.2006
HR12.12.2006
LV12.12.2006
MK12.12.2006
YU12.12.2006
TitleGerman:ALS LIGANDEN DES HISTAMIN-H3-REZEPTORS GEEIGNETE TETRAHYDRONAPHTHYRIDINDERIVATE[2007/09]
English:TETRAHYDRONAPHTHYRIDINE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS[2007/09]
French:DERIVES DE TETRAHYDRONAPHTHYRIDINE UTILISES COMME LIGANDS DU RECEPTEUR H3 DE L'HISTAMINE[2007/09]
Entry into regional phase12.12.2006National basic fee paid 
12.12.2006Designation fee(s) paid 
12.12.2006Examination fee paid 
Examination procedure08.07.2005Request for preliminary examination filed
International Preliminary Examining Authority: EP
12.12.2006Examination requested  [2007/09]
12.02.2010Despatch of a communication from the examining division (Time limit: M04)
03.06.2010Reply to a communication from the examining division
19.07.2010Communication of intention to grant the patent
06.10.2010Fee for grant paid
06.10.2010Fee for publishing/printing paid
Opposition(s)16.09.2011No opposition filed within time limit [2011/47]
Fees paidRenewal fee
31.05.2007Renewal fee patent year 03
02.06.2008Renewal fee patent year 04
02.06.2009Renewal fee patent year 05
31.05.2010Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT15.12.2010
BE15.12.2010
CY15.12.2010
CZ15.12.2010
EE15.12.2010
HU15.12.2010
LT15.12.2010
PL15.12.2010
RO15.12.2010
SI15.12.2010
SK15.12.2010
TR15.12.2010
BG15.03.2011
GR16.03.2011
IS15.04.2011
PT15.04.2011
LU06.05.2011
CH31.05.2011
LI31.05.2011
MC31.05.2011
[2013/45]
Former [2013/44]AT15.12.2010
BE15.12.2010
CY15.12.2010
CZ15.12.2010
EE15.12.2010
LT15.12.2010
PL15.12.2010
RO15.12.2010
SI15.12.2010
SK15.12.2010
TR15.12.2010
BG15.03.2011
GR16.03.2011
IS15.04.2011
PT15.04.2011
LU06.05.2011
CH31.05.2011
LI31.05.2011
MC31.05.2011
Former [2013/25]AT15.12.2010
BE15.12.2010
CY15.12.2010
CZ15.12.2010
EE15.12.2010
LT15.12.2010
PL15.12.2010
RO15.12.2010
SI15.12.2010
SK15.12.2010
BG15.03.2011
GR16.03.2011
IS15.04.2011
PT15.04.2011
LU06.05.2011
CH31.05.2011
LI31.05.2011
MC31.05.2011
Former [2012/07]AT15.12.2010
BE15.12.2010
CY15.12.2010
CZ15.12.2010
EE15.12.2010
LT15.12.2010
PL15.12.2010
RO15.12.2010
SI15.12.2010
SK15.12.2010
BG15.03.2011
GR16.03.2011
IS15.04.2011
PT15.04.2011
CH31.05.2011
LI31.05.2011
MC31.05.2011
Former [2012/05]AT15.12.2010
BE15.12.2010
CY15.12.2010
CZ15.12.2010
EE15.12.2010
LT15.12.2010
PL15.12.2010
RO15.12.2010
SI15.12.2010
SK15.12.2010
BG15.03.2011
GR16.03.2011
IS15.04.2011
PT15.04.2011
MC31.05.2011
Former [2011/37]AT15.12.2010
BE15.12.2010
CY15.12.2010
CZ15.12.2010
EE15.12.2010
LT15.12.2010
PL15.12.2010
RO15.12.2010
SI15.12.2010
SK15.12.2010
BG15.03.2011
GR16.03.2011
IS15.04.2011
PT15.04.2011
Former [2011/36]AT15.12.2010
BE15.12.2010
CY15.12.2010
CZ15.12.2010
EE15.12.2010
LT15.12.2010
PL15.12.2010
SI15.12.2010
SK15.12.2010
BG15.03.2011
GR16.03.2011
IS15.04.2011
PT15.04.2011
Former [2011/35]AT15.12.2010
BE15.12.2010
CY15.12.2010
CZ15.12.2010
EE15.12.2010
LT15.12.2010
SI15.12.2010
BG15.03.2011
GR16.03.2011
IS15.04.2011
PT15.04.2011
Former [2011/32]AT15.12.2010
BE15.12.2010
CY15.12.2010
LT15.12.2010
SI15.12.2010
BG15.03.2011
Former [2011/30]AT15.12.2010
CY15.12.2010
LT15.12.2010
SI15.12.2010
BG15.03.2011
Former [2011/19]LT15.12.2010
Cited inInternational search[AD]WO0212214  (ORTHO MCNEIL PHARM INC [US]) [AD] 1,12-19 * the whole document *;
 [A]EP1295883  (DAINIPPON PHARMACEUTICAL CO [JP]) [A] 1,12-19 * the whole document *;
 [AD]  - H. STARK, "Recent advances in histamine H3/H4 receptor ligands", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS LTD, (2003), vol. 13, no. 6, pages 851 - 865, XP002298271 [AD] 1,12-19 * the whole document *

DOI:   http://dx.doi.org/10.1517/eotp.13.6.851.23016
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.